<?xml version="1.0" encoding="UTF-8"?>
<p>
 <bold>Vaccination:</bold> There were 78 studies evaluating potential vaccine candidates. Twenty-one included 
 <italic>in vitro</italic> experiments, 42 used laboratory animals (mice and rabbits), seven used non-human primates and eight reported results from testing the potential vaccine on humans; 
 <xref rid="pone.0207554.t001" ref-type="table">Table 1</xref>. There was no validated and approved ready-to-use vaccine against chikungunya for humans identified from our data analyses. However, there were articles on two potential vaccine candidates. One demonstrated complete immunity against CHIKV in mice and NHPs [
 <xref rid="pone.0207554.ref273" ref-type="bibr">273</xref>], while the other, a novel live-attenuated vaccine candidate, has undergone a phase II clinical trial and is suggested as an option for emergency CHIKV vaccinations, in addition to being a potential vaccine candidate that can be further developed [
 <xref rid="pone.0207554.ref274" ref-type="bibr">274</xref>].
</p>
